Cost-Effectiveness of Device-Aided Therapies in Parkinson's Disease: A Structured Review.
Parkinson’s disease
continuous subcutaneous apomorphine infusion
cost-effectiveness
deep brain stimulation
levodopa-carbidopa intestinal gel
quality adjusted life year
Journal
Journal of Parkinson's disease
ISSN: 1877-718X
Titre abrégé: J Parkinsons Dis
Pays: Netherlands
ID NLM: 101567362
Informations de publication
Date de publication:
2021
2021
Historique:
pubmed:
3
1
2021
medline:
15
12
2021
entrez:
2
1
2021
Statut:
ppublish
Résumé
Despite optimal dopaminergic treatment most patients in moderate to advanced stages of Parkinson's disease (PD) experience progressively increasing disabilities, necessitating a shift from oral medication to device-aided therapies, including deep brain stimulation (DBS), intrajejunal levodopa-carbidopa infusion (IJLI), and continuous subcutaneous apomorphine infusion (CSAI). However, these therapies are costly, limiting their implementation. To perform a systematic review on cost-effectiveness analyses for device-aided therapies in PD. References were identified by performing a systematic search in the PubMed and Web of Science databases in accordance with the PRISMA statement. In the absence of universal cost-effectiveness definitions, the gross domestic product per capita (GDP) in the country where a study was performed was used as a cut-off for cost-effectiveness based on cost per quality adjusted life year (QALY) gained. In total 30 studies were retrieved. All device-aided therapies improved quality of life compared to best medical treatment, with improvements in QALYs between 0.88 and 1.26 in the studies with long temporal horizons. For DBS, nearly all studies showed that cost per QALY was below the GDP threshold. For infusion therapies only three studies showed a cost per QALY below this threshold, with several studies with long temporal horizons showing costs below or near the GDP threshold. Of the device-aided therapies, DBS can be considered cost-effective, but the majority of infusion therapy studies showed that these were less cost-effective. However, long-term use of the infusion therapies appears to improve their cost-effectiveness and in addition, several strategies are underway to reduce these high costs.
Sections du résumé
BACKGROUND
Despite optimal dopaminergic treatment most patients in moderate to advanced stages of Parkinson's disease (PD) experience progressively increasing disabilities, necessitating a shift from oral medication to device-aided therapies, including deep brain stimulation (DBS), intrajejunal levodopa-carbidopa infusion (IJLI), and continuous subcutaneous apomorphine infusion (CSAI). However, these therapies are costly, limiting their implementation.
OBJECTIVES
To perform a systematic review on cost-effectiveness analyses for device-aided therapies in PD.
METHODS
References were identified by performing a systematic search in the PubMed and Web of Science databases in accordance with the PRISMA statement. In the absence of universal cost-effectiveness definitions, the gross domestic product per capita (GDP) in the country where a study was performed was used as a cut-off for cost-effectiveness based on cost per quality adjusted life year (QALY) gained.
RESULTS
In total 30 studies were retrieved. All device-aided therapies improved quality of life compared to best medical treatment, with improvements in QALYs between 0.88 and 1.26 in the studies with long temporal horizons. For DBS, nearly all studies showed that cost per QALY was below the GDP threshold. For infusion therapies only three studies showed a cost per QALY below this threshold, with several studies with long temporal horizons showing costs below or near the GDP threshold.
CONCLUSION
Of the device-aided therapies, DBS can be considered cost-effective, but the majority of infusion therapy studies showed that these were less cost-effective. However, long-term use of the infusion therapies appears to improve their cost-effectiveness and in addition, several strategies are underway to reduce these high costs.
Identifiants
pubmed: 33386813
pii: JPD202348
doi: 10.3233/JPD-202348
pmc: PMC8150660
doi:
Substances chimiques
Antiparkinson Agents
0
Levodopa
46627O600J
Apomorphine
N21FAR7B4S
Types de publication
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
475-489Références
J Parkinsons Dis. 2018;8(s1):S65-S72
pubmed: 30584160
Bull World Health Organ. 2015 Feb 1;93(2):118-24
pubmed: 25883405
Mov Disord. 2019 Mar;34(3):353-365
pubmed: 30719763
J Med Econ. 2011;14(1):130-9
pubmed: 21235405
Front Neurol. 2012 Apr 26;3:66
pubmed: 22557991
Expert Rev Pharmacoecon Outcomes Res. 2015;15(6):889-911
pubmed: 26511768
PLoS One. 2016 Jul 21;11(7):e0159340
pubmed: 27441637
J Med Econ. 2015 Feb;18(2):155-65
pubmed: 25348011
Appl Health Econ Health Policy. 2009;7(3):167-80
pubmed: 19799471
Appl Health Econ Health Policy. 2010;8(6):377-86
pubmed: 21043539
Arq Neuropsiquiatr. 2018 Dec;76(12):840-848
pubmed: 30698208
Parkinsonism Relat Disord. 2015 Oct;21(10):1133-44
pubmed: 26233582
Mov Disord. 2007 Nov 15;22(15):2183-91
pubmed: 17724747
J Med Econ. 2011;14(5):584-93
pubmed: 21728911
OECD Obs. 1985 Sep;(136):9-12
pubmed: 12267642
Parkinsonism Relat Disord. 2011 Jun;17(5):360-4
pubmed: 21396874
J Neurol. 2005 Feb;252(2):218-23
pubmed: 15729530
Curr Med Res Opin. 2018 Dec;34(12):2063-2073
pubmed: 30016901
Int J Clin Pract. 2016 Nov;70(11):907-915
pubmed: 27870257
Eur J Neurol. 2019 Apr;26(4):581-e43
pubmed: 30353942
J Neurol. 2013 Nov;260(11):2701-14
pubmed: 23287972
Mov Disord. 2007 Apr 30;22(6):804-12
pubmed: 17290462
Glob Health Action. 2018;11(1):1447828
pubmed: 29564962
Neurol Clin. 2020 May;38(2):255-267
pubmed: 32279709
Intern Med J. 2018 Apr;48(4):472-474
pubmed: 29623993
Mov Disord. 2016 Aug;31(8):1183-91
pubmed: 27506638
Rev Neurol. 2016 Dec 16;63(12):529-536
pubmed: 27897303
Neuromodulation. 2016 Oct;19(7):689-697
pubmed: 27491661
Mov Disord. 2017 Feb;32(2):283-286
pubmed: 27987231
Nat Rev Neurosci. 2017 Jul;18(7):435-450
pubmed: 28592904
Eur Neuropsychopharmacol. 2011 Feb;21(2):180-91
pubmed: 20888737
Can J Neurol Sci. 2016 Jul;43(4):462-71
pubmed: 27139127
Neurol Med Chir (Tokyo). 2016 Oct 15;56(10):613-625
pubmed: 27349658
CMAJ. 1992 Feb 15;146(4):473-81
pubmed: 1306034
JAMA Neurol. 2018 Jan 1;75(1):9-10
pubmed: 29131880
World Neurosurg. 2016 May;89:628-635.e1
pubmed: 26704203
J Med Econ. 2017 Nov;20(11):1207-1215
pubmed: 28895769
Ann Neurol. 2013 May;73(5):565-75
pubmed: 23483564
Mov Disord. 2015 Apr;30(4):510-6
pubmed: 25382161
Mov Disord. 2010 Jul 30;25(10):1456-63
pubmed: 20629150
J Parkinsons Dis. 2016 Jul 25;6(3):533-43
pubmed: 27472888
Rev Neurol (Paris). 1989;145(4):320-3
pubmed: 2660224
J Neurol. 2014 Dec;261(12):2438-45
pubmed: 25270681
J Med Econ. 2013;16(2):191-201
pubmed: 23035627
Value Health. 2014 Nov;17(7):A395
pubmed: 27200927
Front Neurol. 2019 Aug 16;10:896
pubmed: 31474936
J Clin Epidemiol. 2009 Oct;62(10):e1-34
pubmed: 19631507
Brain Stimul. 2016 Jan-Feb;9(1):78-85
pubmed: 26385442
World Neurosurg. 2014 Dec;82(6):987-93
pubmed: 25175275
Mov Disord. 2016 Sep;31(9):1258-62
pubmed: 27501323
Mov Disord. 2018 Jul;33(6):900-908
pubmed: 29570862
J Neurol. 2002 Jun;249(6):759-66
pubmed: 12111311
Eur J Epidemiol. 2011 Jun;26 Suppl 1:S1-58
pubmed: 21626386
Parkinsonism Relat Disord. 2016 Aug;29:17-23
pubmed: 27318707
Neurology. 2013 Feb 26;80(9):800-9
pubmed: 23365054
Parkinsonism Relat Disord. 2012 Sep;18(8):916-29
pubmed: 22824056
Neuromodulation. 2017 Apr;20(3):243-247
pubmed: 28083888
Soc Justice Res. 2019;32(2):208-238
pubmed: 31281204
J Med Econ. 2019 Mar;22(3):215-225
pubmed: 30484353
J Neurol. 2014 Jan;261(1):106-16
pubmed: 24158271
Lancet. 2002 May 4;359(9317):1589-98
pubmed: 12047983
BMC Neurol. 2020 Jan 31;20(1):40
pubmed: 32005175
Mov Disord. 2016 Aug;31(8):1173-82
pubmed: 26846185
Mov Disord. 2013 Jun;28(6):763-71
pubmed: 23576266
Neurology. 2001 Aug 28;57(4):663-71
pubmed: 11524476
World Neurosurg. 2015 Oct;84(4):1020-9
pubmed: 26038334
J Parkinsons Dis. 2020;10(4):1535-1539
pubmed: 32597817
Mov Disord. 2018 Mar;33(3):421-430
pubmed: 29465787